( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 301 | Macular dystrophy | 46 |
301. Macular dystrophy
Clinical trials : 46 / Drugs : 42 - (DrugBank : 11) / Drug target genes : 9 - Drug target pathways : 67
Showing 1 to 10 of 46 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05417126 (ClinicalTrials.gov) | July 5, 2022 | 9/6/2022 | Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects Wi ... | A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Int ... | Stargardt Disease | Biological: Gene Therapy-vMCO-010 | Nanoscope Therapeutics Inc. | NULL | Active, not recruiting | 16 Years | N/A | All | 6 | Phase 2 | United States |
| 2 | NCT05244304 (ClinicalTrials.gov) | March 28, 2022 | 20/1/2022 | Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1 Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Ad ... | Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and ... | Stargardt Disease 1 | Drug: Tinlarebant;Drug: Placebo | Belite Bio, Inc | NULL | Recruiting | 12 Years | 18 Years | All | 60 | Phase 3 | China;France;Germany;Hong Kong;Netherlands;Switzerland;Taiwan;United Kingdom;Australia;Belgium;United States China;France;Germany;Hong Kong;Netherlands;Switzerland;Taiwan;United Kingdom;Australia;Belgium;Unite ... |
| 3 | NCT05266014 (ClinicalTrials.gov) | March 12, 2021 | 26/1/2022 | This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability ... | Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolera ... | Stargardt Disease | Drug: tinlarebant | RBP4 Pty Ltd | Belite Bio, Inc | Active, not recruiting | 12 Years | 18 Years | All | 13 | Phase 1/Phase 2 | Australia;Taiwan |
| 4 | NCT04658251 (ClinicalTrials.gov) | March 3, 2021 | 1/12/2020 | Study of New Mutations in Cone Disorders | Functional Study of Intronic Variants in Inherited Cone Disorders | Retinal Dystrophy, Cone-Rod;Cone Dystrophy;Cone Rod Dystrophy;Macular Degeneration | Genetic: Blood and/or skin biopsy | University Hospital, Lille | NULL | Recruiting | 3 Years | N/A | All | 20 | France | |
| 5 | NCT04545736 (ClinicalTrials.gov) | November 23, 2020 | 10/9/2020 | Oral Metformin for Treatment of ABCA4 Retinopathy | Oral Metformin for Treatment of ABCA4 Retinopathy | ABCA4 Retinopathy;Stargardt Disease;Retinal Dystrophy;Retinal Degeneration | Drug: Metformin hydrochloride | National Eye Institute (NEI) | NULL | Recruiting | 12 Years | N/A | All | 38 | Phase 1/Phase 2 | United States |
| 6 | NCT04489511 (ClinicalTrials.gov) | October 1, 2020 | 21/7/2020 | Study of STG-001 in Subjects With Stargardt Disease | A Phase 2a Study of the Safety, Pharmacokinetics and Pharmacodynamics of STG-001 in Subjects With Stargardt Disease (STGD1) Caused by Autosomal Recessive Mutation in ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene A Phase 2a Study of the Safety, Pharmacokinetics and Pharmacodynamics of STG-001 in Subjects With St ... | Stargardt Disease-1 | Drug: STG-001 | Stargazer Pharmaceuticals, Inc. | NULL | Completed | 18 Years | 55 Years | All | 10 | Phase 2 | United States |
| 7 | NCT04239625 (ClinicalTrials.gov) | December 20, 2019 | 11/1/2020 | Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) | A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long T ... | Stargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Stargardt Disease 1 (ABCA4-related) Stargardt Disease;Stargardt Macular Degeneration;Stargardt Macular Dystrophy;Autosomal Recessive Sta ... | Drug: ALK-001 | Alkeus Pharmaceuticals, Inc. | NULL | Enrolling by invitation | 8 Years | 70 Years | All | 140 | Phase 2 | United States |
| 8 | EUCTR2018-001496-20-IT (EUCTR) | 18/07/2019 | 17/06/2021 | A phase II study of soraprazan in patients with Stargardt disease | A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease - SMR3438 A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate ... | Stargardt Disease <br>MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] Stargardt Disease <br>MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's ... | Product Name: soraprazan<br>Product Code: [EU/3/13/1208 orphan]<br>INN or Proposed INN: (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine Product Name: soraprazan<br>Product Code: [EU/3/13/1208 orphan]<br>INN or Proposed INN: (7R,8R,9R)-2 ... | Katairo GmbH | NULL | Authorised-recruitment may be ongoing or finished | <an>br>Female: yes Male: yes | 90 | Phase 2 | Netherlands;Germany;United Kingdom;Italy | ||
| 9 | EUCTR2018-003498-82-DK (EUCTR) | 11/06/2019 | 17/12/2018 | Evaluation of Emixustat for the Treatment of Stargardt Disease | A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride with Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease - The SeaSTAR Study (Safety and efficacy of EmixustAt in STARgardt disease) A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixusta ... | Stargardt Disease <br>MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] Stargardt Disease <br>MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's ... | Product Name: Emixustat hydrochloride<br>Product Code: ACU-4429<br>INN or Proposed INN: Emixustat hydrochloride<br>Other descriptive name: EMIXUSTAT HYDROCHLORIDE (ACU-4429)<br>Product Name: Emixustat hydrochloride<br>Product Code: ACU-4429<br>INN or Proposed INN: Emixustat hydrochloride<br>Other descriptive name: EMIXUSTAT HYDROCHLORIDE (ACU-4429) Product Name: Emixustat hydrochloride<br>Product Code: ACU-4429<br>INN or Proposed INN: Emixustat hy ... | Acucela Inc. | NULL | Not Recruiting | <an>br>Female: yes Male: yes | 194 | Phase 3 | United States;France;Canada;Spain;Brazil;Denmark;South Africa;Netherlands;Germany;United Kingdom;Italy United States;France;Canada;Spain;Brazil;Denmark;South Africa;Netherlands;Germany;United Kingdom;Ita ... | ||
| 10 | EUCTR2018-003498-82-IT (EUCTR) | 29/05/2019 | 13/01/2021 | Evaluation of Emixustat for the Treatment of Stargardt Disease | A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride with Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease - The SeaSTAR Study (Safety and efficacy of EmixustAt in STARgardt disease) A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixusta ... | A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride with Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease <br>MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixusta ... | Product Name: Emixustat hydrochloride<br>Product Code: [ACU-4429]<br>INN or Proposed INN: Emixustat hydrochloride<br>Product Name: Emixustat hydrochloride<br>Product Code: [ACU-4429]<br>INN or Proposed INN: Emixustat hydrochloride Product Name: Emixustat hydrochloride<br>Product Code: [ACU-4429]<br>INN or Proposed INN: Emixustat ... | Acucela Inc. | NULL | Authorised-recruitment may be ongoing or finished | <an>br>Female: yes Male: yes | 162 | Phase 3 | France;United States;Canada;Spain;Brazil;Denmark;South Africa;Netherlands;Germany;United Kingdom;Italy France;United States;Canada;Spain;Brazil;Denmark;South Africa;Netherlands;Germany;United Kingdom;Ita ... |